BioIVT

Your partner in ELEVATING SCIENCE.

[BioIVT @BioIVT]

What does it take to move #NewApproachMethodologies from promising research alternatives to reliable research tools? In our latest blog, we explore important considerations in successful implementation of #NAMs: https://t.co/2Gxvwv7d5O

[BioIVT @BioIVT]

From compound structures to entirely different modalities, drugs differ drastically from each other. So, why rubber stamp the same #ADME/#DDI studies? Get expert guidance on fit-for-purpose program & #StudyDesign: https://t.co/6nEPz7L30G

#DMPK #DrugInteractions #DrugMetabolism

[BioIVT @BioIVT]

Testing for potential #DrugInteractions is an important part of assessing the safety of new drug candidates & includes a variety of different studies, such as enzyme induction. Watch an overview of important considerations when evaluating CYP induction: https://t.co/Ksn43vCoEb

[BioIVT @BioIVT]

Heterogeneity has a big impact on #autoimmune research. From discovery through development, we help researchers obtain the right biology, donor context & sample quality to generate more relevant, reproducible & translationally meaningful insights: https://t.co/9y6SVIruJo

[BioIVT @BioIVT]

As research becomes more precise, researchers are placing more emphasis on #biospecimen quality, clinical context, and suitability. BioIVT's global sourcing network helps researchers understand the full story behind each biospecimen: https://t.co/gk79wwZMXA

[BioIVT @BioIVT]

New #ADME research shedding light on how hepatic drug-metabolizing #hydrolases carry across demographics. Using BioIVT human #hepatocytes, researchers evaluated 239 hydrolases to explore differences associated with age, sex, and race. Read the full study: https://t.co/LsjpHPlHoi

[BioIVT @BioIVT]

Did you miss any of our presentations at the #ISSX2026? No problem!

View the posters: https://t.co/ZwPyP2J2Xc)
Hear the #GLP1 #PeptideTherapeutics case study: https://t.co/1oOzig45I2
See the #BloodBrainBarrier #DrugTransporters presentation: https://t.co/djVCzvnZOB

[BioIVT @BioIVT]

Join us for a Spanish webinar on how biologists transform donated tissues into high-quality resources that support advanced #Preclinical and #TranslationalResearch, including best practices in tissue procurement, processing & traceability: https://t.co/IPdrSi8T0l

#OrganDonation

[BioIVT @BioIVT]

What happens when your study requires highly specific donor samples and hundreds of millions of #PBMCs per donor?

See how BioIVT helped an #immunology research team recruit and qualify #MultipleSclerosis #donors through a prospective collection strategy: https://t.co/Kf9O2Q1RGL

[BioIVT @BioIVT]

After our last #LiquidBiopsy presentation sparked such great questions, we expanded those insights into a 44-page guide covering key variables that can impact sample quality and downstream results.

Explore all seven chapters in the full 44-page guide: https://t.co/YxDbzB9DwI

[BioIVT @BioIVT]

Our Oct. newsletter includes updates on the latest science, resources, and expert perspectives from BioIVT on topics including #immunology, #ADME, #liquidbiopsy, #NAMS and #toxicity. Read now: https://t.co/WBArpd28sp

[BioIVT @BioIVT]

As year-end ordering ramps up, availability of high-demand disease-state biospecimens like #serum, #plasma, #CSF and #tissuesamples can change quickly. Don’t wait until demand picks up to start looking for the specimens your research needs: https://t.co/ZKXVmpSbJz

[BioIVT @BioIVT]

Our team is ready at #ISSX2026 booth #504 to discuss your #ADME/#DMPK questions & needs! And don’t miss our exciting presentation lineup: https://t.co/aoldLeUjRL

#DrugMetabolism #DrugInteractions #GLP1 #PeptideTherapeutics #BloodBrainBarrier #Bioinformatics #siRNA #MASLD

[BioIVT @BioIVT]

At BioIVT, our mission centers on advancing scientific discovery powered by individuals who support research through our donor programs. Learn how you can participate ⬇️

US: https://t.co/itJNLR201f
UK: https://t.co/NlVOaJIUOn

[BioIVT @BioIVT]

Did you miss our #DMDG-#GMP-#SPS Joint Meeting poster? "In Vitro Lysosomal Catabolism of #GLP1 #PeptideTherapeutics: A Human vs. Rat Species Comparison" is now available to download from our website: https://t.co/InV6Yo92U4

#ScientificPoster #Lysosomes #ADME #DrugMetabolism

[BioIVT @BioIVT]

At the 9th TPD & Induced Proximity Summit, BioIVT's Tina Mueller, PhD, will present “The In Vitro #ADME Playbook for #ProteinDegraders: What’s Different?” on October 27 at 1:30 pm. Learn more and request a meeting with our team: https://t.co/31TUU0DdzV

[BioIVT @BioIVT]

We’re 2 weeks out from our upcoming webinar, #MetabolicDisease #DrugDevelopment: Translational Models and a #GLP1 Receptor Agonist Metabolism Case Study.  

Register today: https://t.co/AUxFgRNOAt

#ADME #DMPK #TherapeuticProteins #DrugMetabolism

[BioIVT @BioIVT]

Mark your AAPS #PharmSci360 agendas! Dr. Grindstaff will be moderating a fantastic lineup of expert presentations on “Model-Informed Innovation: Integrating #NAMs Across Translational Workflows” on Tuesday, October 27: https://t.co/gxVxSDWXP0

#ADME #Biospecimens #DrugDevelopment

[BioIVT @BioIVT]

Across 3 decades Mark Warren has worked with clients to design & complete more than 1000 #DrugTransporters studies. In his #MeetTheExpert interview, Mark shares what 30 years in the field have taught him about transporters & their role in #DrugDevelopment: https://t.co/pXwBZkQU7E

[BioIVT @BioIVT]

Understanding autoimmune, inflammatory, and allergic disease means accounting for patient-to-patient variability. From HLA type to disease state and clinical history, biological context matters. Explore BioIVT’s immunology research solutions: https://t.co/zrVOUfXgwN